It can help high-income earners save a lot of money in retirement.
Following European approval earlier this month, bluebird bio announced its beta-thalassemia gene therapy will launch with a sky-high price tag.
Surging sales were shy of industry watchers' expectations, but management's guidance shows it's unfazed by a quarterly slowdown.
Updated data from a late-stage trial of voxelotor fell shy of investors' expectations.
Here are this year's winners and losers following the Super Bowl of biotech conferences.
Here's why it could be the perfect time to add these income stocks to your portfolio.
Investors will get additional insight into a potential new treatment for sickle cell disease on Friday.
These big-cap technology companies could be bargains worth buying.
Shock waves from a competitor's stumble sent the clinical-stage biotech's shares reeling.
European regulators have signed off on the biotech's revolutionary gene therapy for beta-thalassemia.
These top healthcare stocks could be worth adding to portfolios if the market sells off sharply.
The sky-high price of this revolutionary new gene therapy may not be as crazy as it seems.
The company is riding high following FDA clearance for its tattoo removal medical device.
Sales are soaring at this marijuana stock, but rising revenue isn't the only thing you should know about its performance last quarter.
The latest trial results for its hemophilia A gene therapy suggest it may eliminate or significantly reduce the need for weekly infusions.
Increasing demand for its forecasting software is sending sales soaring.
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
These biotech stocks could pop or drop next month following ASCO's annual conference.
The clinical-stage developer of RNAi therapies is being added to the S&P 600 index.
Berkshire Hathaway is the single largest shareholder of these well-known companies.